Spirogen Ltd Company Profile
Spirogen was founded in 2001 as a spin-out from several institutions including University College London. Since that time, it has developed a novel class of highly potent cytotoxic warheads based on its proprietary pyrrolobenzodiazepines (PBDs), DNA minor groove binding agents, which bind and cross-link specific sites of DNA of the cancer cell. This blocks the cancer cells’ division without distorting its DNA helix, thus avoiding the common phenomenon of emergent drug resistance. In contrast, many cancer chemotherapeutics distort the structure of DNA resulting in the ability to the cancer cells to develop resistance to further therapy. Spirogen has been developing its PBD technology for more than 10 years, including a PBD agent already in an NCI-sponsored Phase II study in cisplatin resistant ovarian cancer. Its business model is to partner its technology with pharma and biotech for use in the development of novel drugs. It has a number of industry collaborations, including a collaboration with Genentech announced in 2011. Spirogen is financed and majority owned by Celtic Therapeutics Management L.L.L.P.
Location
University of London
29-39 Brunswick Square
London
London
W1CN 1AX
United Kingdom
Contact
Phone: 44 (0)207 278 0555
Fax: 44 (0)207 278 2888
Email: info@spirogen.com
News Articles
Ablynx, Spirogen set to evaluate novel anti-cancer drug conjugates
Ablynx and Spirogen have entered into a research collaboration to study and analyse the potential of a novel anti-cancer drug conjugate that combines Spirogen's proprietary cytotoxic drugs, pyrroloben...
Ablynx and Spirogen enter in research collaboration for toxin-nanobody drug conjugates
Ablynx and Spirogen Ltd. announced a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PB...
Briefs: Ablynx inks research deal with Spirogen; Solent Pharma debuts
Belgium drug developer Ablynx (Euronext Brussels: ABLX) has entered into a research collaboration with closely-held UK-based Spirogen to evaluate the potential of a novel anti-cancer drug conjugate c...
Ablynx and Spirogen to evaluate toxin-nanobody drug conjugates
Will combine Spirogen pyrrolobenzodiazepines with Ablynx nanobodies
Ablynx inks deal with Spirogen to evaluate novel anti-cancer drug conjugate
Ablynx has signed a collaborative agreement with Spirogen to evaluate the potential of a novel anti-cancer drug conjugate.
Novel anti-cancer drug conjugates to be evaluated by Ablynx and Spirogen
Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, p...
GHENT, Belgium and LONDON, United Kingdom, 25 February 2013 - Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer ...
2nd Annual ADC Summit 2013 London, 20-21 May
SMi's ADC Summit 2013 has returned and will be held on the 20th to 21st May. This year's event will present a unique insight into latest technological and scientific developments and will be the perfe...
Drugs and Medications
None
PubMed Articles
The pyrrolobenzodiazepines (PBDs) are naturally occurring antitumor antibiotics and a PBD dimer (SJG-136, SG2000) is in Phase II trials. SG2000 is a propyldioxy linked PBD dimer which binds sequence s...
Clinical Trials
None
Companies
Spirogen was founded in 2001 as a spin-out from several institutions including University College London. Since that time, it has developed a novel class of highly potent cytotoxic warheads ba...
Spirogen Limited (âSpirogenâ) was founded in 2001 as a spin-out from several institutions including University College, London. Since that time, it has developed a novel...
Auven Therapeutics is a private equity company focused on the healthcare industry. The Company’s strategy is to acquire controlling ownership in promising therapeutic products or platforms....
More Information about "Spirogen Ltd" on BioPortfolio
We have published hundreds of Spirogen Ltd news stories on BioPortfolio along with dozens of Spirogen Ltd Clinical Trials and PubMed Articles about Spirogen Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Spirogen Ltd Companies in our database. You can also find out about relevant Spirogen Ltd Drugs and Medications on this site too.
